Summit Therapeutics (SMMT) Earnings Date, Estimates & Call Transcripts $19.00 +0.58 (+3.15%) (As of 11/22/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Summit Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSMMT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SMMT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly repeat itself with the AI frenzy. I urge you to watch it before you invest another cent. Again, to be clear, I’m no Chicken Little. Far from it. So go here now to read my new report The Big AI Die-Up… while you still can. Summit Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ3 20241-$0.06-$0.06-$0.06Q4 20241-$0.06-$0.06-$0.0620242-$0.12-$0.12-$0.12Q1 20251-$0.06-$0.06-$0.06Q2 20251-$0.06-$0.06-$0.06Q3 20251-$0.07-$0.07-$0.07Q4 20251-$0.07-$0.07-$0.07FY 20254($0.26)($0.26)($0.26) Summit Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/18/2025(Estimated)------- 8/6/2024Q2 2024-$0.06-$0.05+$0.01-$0.01--5/1/2024Q1 2024-$0.06-$0.05+$0.01-$0.04-- 2/20/2024Q4 2023--$0.05 -$0.05-$0.05-$0.20M 11/7/2023Q3 2023--$0.03 -$0.03-$0.03-$0.27M 8/9/2023Q2 2023--$0.02 -$0.02-$0.02-- 5/11/2023Q1 2023--$0.06 -$0.06$1.31-- Nvidia’s world of pain awaits (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Click play to stream The Final Frontier at no cost3/9/2023Q4 2022--$0.07 -$0.07-$0.07-$1.13M Summit Therapeutics Earnings - Frequently Asked Questions When is Summit Therapeutics's earnings date? Summit Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based off last year's report dates. Learn more on SMMT's earnings history. How much revenue does Summit Therapeutics generate each year? Summit Therapeutics (NASDAQ:SMMT) has a recorded annual revenue of $700,000.00. How much profit does Summit Therapeutics generate each year? Summit Therapeutics (NASDAQ:SMMT) has a recorded net income of -$614.93 million. SMMT has generated -$0.28 earnings per share over the last four quarters. What is Summit Therapeutics's EPS forecast for next year? Summit Therapeutics's earnings are expected to decrease from ($0.30) per share to ($0.33) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Takeda Pharmaceutical Earnings Results BioNTech Earnings Results Teva Pharmaceutical Industries Earnings Results BeiGene Earnings Results Viatris Earnings Results Moderna Earnings Results Genmab A/S Earnings Results Dr. Reddy's Laboratories Earnings Results Vaxcyte Earnings Results Catalent Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report The pin that pops the AI bubble (Ad)My new documentary explores the background to this pattern and how and why I believe it will almost certainly repeat itself with the AI frenzy. I urge you to watch it before you invest another cent. Again, to be clear, I’m no Chicken Little. Far from it. So go here now to read my new report The Big AI Die-Up… while you still can. This page (NASDAQ:SMMT) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredReality Check: Are You Prepared for What's Next?Global shifts, like the alliance of BRICS nations pushing for economic independence from the U.S. dollar, and ...Allegiance Gold | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
